Latest Safety News

Page 11 of 145
Aura Energy’s 2025 AGM highlights strong uranium market fundamentals and strategic progress on its Tiris Project, despite some engineering delays. The company also strengthens its board and deepens ties in Mauritania as it prepares for production.
Maxwell Dee
Maxwell Dee
25 Nov 2025
Monadelphous has reported a record-breaking year with $2.3 billion in new contracts and a strong financial performance, underpinned by strategic acquisitions and growth in energy transition sectors.
Victor Sage
Victor Sage
25 Nov 2025
Monadelphous Group Limited reported a robust FY25 with record contract wins and a 30% revenue surge, setting the stage for continued growth in FY26. The company’s strategic acquisitions and energy transition focus underpin its optimistic outlook.
Victor Sage
Victor Sage
25 Nov 2025
Renascor Resources has hit key construction milestones at its Australian Government co-funded Purified Spherical Graphite (PSG) demonstration facility, maintaining schedule for on-site commissioning this quarter. The project aims to establish a competitive, HF-free PSG supply chain outside China.
Maxwell Dee
Maxwell Dee
25 Nov 2025
Aroa Biosurgery reported a 14% rise in product sales to NZ$44.6 million for the half-year ended September 2025, driven by strong growth in its Myriad portfolio. The company also posted a normalised EBITDA profit and reaffirmed its FY26 revenue and profit guidance.
Ada Torres
Ada Torres
25 Nov 2025
Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.
Ada Torres
Ada Torres
24 Nov 2025
Cynata Therapeutics has completed the final patient visit in its Phase 3 trial for CYP-004, targeting knee osteoarthritis, with results expected in mid-2026. This milestone advances hopes for a disease-modifying therapy in a market desperate for new options.
Ada Torres
Ada Torres
24 Nov 2025
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for PYC-003, an RNA therapy targeting Polycystic Kidney Disease. This milestone moves the drug closer to pivotal Phase 2/3 trials.
Ada Torres
Ada Torres
24 Nov 2025
Verbrec Limited has reported a strong FY2025 with record margins and resumed dividend payments after more than a decade, alongside strategic moves including a key acquisition and divestment.
Victor Sage
Victor Sage
21 Nov 2025
Genesis Minerals has secured crucial rail agreements that clear the path for developing the Tower Hill open pit gold mine and expanding the Leonora mill, targeting first ore in FY28.
Maxwell Dee
Maxwell Dee
21 Nov 2025
Elevra Lithium reports a 31% surge in spodumene concentrate production for FY25, alongside significant resource expansions and a clear growth roadmap post-merger.
Maxwell Dee
Maxwell Dee
21 Nov 2025
Bindi Metals Limited has announced a non-renounceable entitlement offer of options to raise approximately $46,000, underwritten by CPS Capital Group. The offer includes 46 million options to shareholders and 5 million options to the lead manager, with potential dilution if exercised.
Maxwell Dee
Maxwell Dee
21 Nov 2025